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Following radiotherapy, many patients with osteoradionecrosis suffer from xerostomia, thereby decreasing their
quality of life. Patients can develop problems with speech, eating, increased dental caries, dysphagia, fractured
dentition, chronic refractory osteomyelitis and osteoradionecrosis. Symptoms associated with salivary gland
dysfunction can be severe enough that patients terminate the course of their radiotherapy prematurely due to the
decrease in their quality of life. Currently, the only treatments available to patients are palliative. A definitive
treatment has yet to be discovered. Head and neck cancers, which comprise 5% of overall cancer treatments, rank
8th most expensive to treat in the United States today. Hyperbaric oxygen is being considered for the therapy of
radiated salivary glands because it has been shown to stimulate capillary angiogenesis and fibroplasia in radiation
treated tissues. It has been hypothesized that salivary acinar cells undergo apoptosis following radiation therapy.
The purpose of this paper is to discuss the mechanisms of salivary gland injury and evaluate whether hyperbaric
oxygen therapy improves salivary gland function in patients who develop xerostomia and osteoradionecrosis
following head and neck radiation.
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Head and neck cancers account for approximately 5% of
the overall cancers treated in the United States and
ranked the 8th most expensive cancer in the United
States today [1]. There are five primary sites that make
up this group of cancers: larynx, pharynx, oral cavity,
salivary glands, and paranasal sinuses [2]. Of these pa-
tients who undergo standard head and neck radiother-
apy, significant damage to the salivary glands can occur
and result in hyposalivation and xerostomia, which is
the condition of dry mouth caused by decreased saliva-
tion. In addition, hyposalivation is among the most
widely recognized causes of dental caries, and oral dis-
comfort, which includes oral sores, changes in taste, dif-
ficulty chewing, swallowing, and difficulty with speech* Correspondence: tlo@llu.edu
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reproduction in any medium, provided the or[3]. This condition place patients at risk for dental caries
and tooth decay because saliva normally bathes the oral
cavity and acts as a clearing agent [4]. Xerostomia is one
of the most common complications of head and neck ir-
radiation, and essentially all patients that undergo radio-
therapy will develop some form of xerostomia as a result
of damage to their major and minor salivary glands [5].
End-stage complications of hyposalivation include frac-
tured dentition, osteonecrosis, and chronic refractory
osteomyelitis. Patients affected by salivary gland dysfunc-
tion often terminate their radiotherapy course prema-
turely because they become malnourished and
experience a significant decrease in their quality of life
[5]. Intensity-modulated radiation therapy as opposed to
traditional radiation therapy, acupuncture, other masti-
catory or gustatory stimulatory therapies, administration
of cytoprotective agents (i.e. amifostine), stimulation of
residual tissue with cholinergic muscarinic agents (i.e.
pilocarpine and bethanecol), and various lubricating
agents are some options to aid with symptom controlLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that provide short-term alleviation [3]. A more perman-
ent and preventive therapy is yet to be discovered to im-
prove salivary gland function in these patients.
Although it has been suggested that there might be re-
covery of salivary gland function many years after radi-
ation therapy, many have found there is very little
recovery in patients who do not receive salivary gland
sparing techniques; and in patients receiving concomi-
tant chemotherapy the incidence of oral complications is
increased [6]. Research demonstrates that head and neck
radiation affect the major and minor salivary glands, and
the effect on these glands contributes to radiation-
induced temporary or permanent xerostomia [7]. In one
study using high resolution-magnetic resonance imaging
(HR-MRI) for tissue evaluation, there appeared to be ad-
verse morphologic changes in the parotid gland as early
as one to two weeks into the start of radiation therapy
and at lower radiation doses than previously expected
[8]. In addition, comparing serous and mucous-secreting
glands, it has been shown that mucous-secreting glands
are not necessarily more resistant to radiotherapy. There
are no widely accepted methods to protect mucous-
secreting glands because they are in the main treatment
field for most head and neck cancers [9]. However, the
major mucous glands are equally important to salivary
flow rate during the unstimulated rest period, as are the
major serous glands [10]. In one study, no significant
difference was observed between the functional response
of the serous (PAR), and the seromucous (SM)/mucous
(SL) glands on exposure to ionizing irradiation [10]. In
the first two weeks of radiotherapy most of the damage
has already become manifest and an 80% reduction in
salivary flow rate is observed, regardless of the type of
gland [10].
Discussion
Hyperbaric oxygen therapy (HBOT) has been shown to
promote angiogenesis, stem cell recruitment and colla-
gen synthesis by increasing oxygen tension in tissues, es-
pecially irradiated tissues [3,11,12]. HBOT has been used
as a primary and adjunctive treatment for medical con-
ditions ranging from infections to non-healing ischemic
wounds. In head and neck irradiated patients, HBOT is
specifically indicated for those patients within said popu-
lation who have developed osteoradionecrosis (ORN),
and for those who have developed other significant tis-
sue damage that is non-healing. Studies have disproved
the notion that the angiogenic properties brought about
by HBOT increase the potential for recurrence, or in-
duction of neoplastic tissue [13]. When sufficient capil-
lary perfusion develops to eliminate oxygen gradients,
excess or unnecessary angiogenesis is prevented, which
is why perfusion only reaches about 75-85% of that ofnon-irradiated tissue [14]. Therefore, a protocol of 20
HBO treatments prior to surgery in irradiated tissue and
10 treatments post-surgery is most often used as it has
been shown to decrease wound dehiscence, decrease rate
of infection, and decrease wound healing delay that
would lengthen the hospital stay for the patient [14].
Spontaneous and anecdotal reports of improvement in
dry mouth at the Copenhagen University Hospital led to
a pilot study evaluating the effect of HBOT on salivary
flow rate in previously head and neck irradiated patients
[3]. According to their data, there was a significant de-
crease in xerostomia as well as hyposalivation in the pa-
tients evaluated [3]. A subsequent study was conducted
by a group of investigators to evaluate the effect HBOT
has on salivary flow rate, pH, and salivary bacteria in-
volved in head and neck irradiated patients. These re-
sults showed that HBOT may be able to decrease caries
risk due to its beneficial effects on pH, bacterial load in
the oral cavity, and salivary flow [14]. In addition, this
study established that the amount of saliva needed to
avoid clinical xerostomia is an unstimulated flow rate of
at least 0.1-0.3 ml/min [15,16]. The limitation of these
two studies is that they lack a control group.
In a study evaluating salivary glands with post-
radiation dysfunction, an increase in the preservation of
specialized tissues was demonstrated following HBOT
[17]. The result of radiation creates what has been called
a “3 H” effect on the tissue: hypovascular, hypocellular,
and hypoxic [18]. When normal tissues are damaged
they develop a central area of tissue injury, or
hematoma, surrounded by normal tissue; the oxygen
tension in the central area is low, whereas adjacent tis-
sues have normal oxygen tension, creating a steep oxy-
gen gradient over a short distance. This induces the
necessary cellular factors to aggregate for capillary bud-
ding, and collagen synthesis needed for wound healing
[19]. In irradiated tissue there is a largely diffuse pattern
of tissue injury that creates a shallow oxygen gradient,
which induces no physiochemical response; the body
does not recognize the irradiated tissue as a wound, and
development of a “3 H” pattern minimizes the natural
tissue oxygen gradient [18]. Irradiated tissue therefore
does not spontaneously re-vascularize, or become re-
perfused, like other tissues because of the “unique phys-
ics and pattern of tumoricidal radiation delivery” that es-
tablishes this pattern of injury [14]. HBOT has been
shown to induce angiogenesis in radiation damaged tis-
sue by infusing the tissues with oxygen and temporarily
simulating the steep oxygen gradient across the
wounded tissue that mimics normal tissue damage;
therefore, the same regulatory control for angiogenesis
in normal tissues is applied to radiation damaged tissue
[12]. HBOT stimulates capillary angiogenesis and fibro-
plasia in tissues radiated with a dose exceeding 5,000
Hadley et al. Medical Gas Research 2013, 3:15 Page 3 of 5
http://www.medicalgasresearch.com/content/3/1/15cGy [12]. Studies show that HBOT enhances fibroblastic,
osteoblastic, osteoclastic, and angioblastic activities in
bones [3,17]. Healing of the wounded tissue occurs as a
gradual process and it was found that the key time
frames where the most significant improvements were
seen after the 10th, 18th, and 20th hyperbaric oxygen
exposures [14]. The optimal dosage for hyperbaric oxy-
gen treatment is 2.0 to 2.5 ATA (atmosphere absolute)
for 90 minutes duration, five days a week over a 20-
session treatment course [12].
It is anticipated that if vascular supply to the irradiated
salivary gland tissues can be restored, enabling tissue re-
generation, near-normal to normal salivary flow can also
be restored. Findings in patients undergoing HBOT for
the treatment of ORN recently lead to a pilot study in
this field that demonstrated that those patients who
were treated with HBOT post-radiotherapy reported a
decrease in xerostomia as well as a clinical increase in
saliva production [3]. Aside from this, a limited number
of studies have been conducted to evaluate the effects of
HBO therapy on irradiated salivary gland tissues [15]. A
major limitation of previous studies was that they lacked
a control group. Further research in this area utilizing a
control group and evaluating specific elements of gland
function may be future targets for therapy.
Changes in the oral microbial flora have also been
reported in patients who have received head and neck
radiation therapy. Following radiotherapy, patients have
been shown to prefer soft and carbohydrate-rich foods
[20]. With decreased salivary flow rate, oral clearance of
sugar is prolonged, which can amplify the rapid progres-
sion of radiation caries [15]. Many studies show that S.
mutans, Lactobacillus spp., and C. albicans can all in-
crease following a physiologic change such as radiation
therapy of the head and neck. S. mutans are the primary
cause of bacteriological caries, and are found in high
amounts in patients following radiation therapy. These
bacteria metabolize sugars to produce acids capable of
dissolving tooth enamel, which eventually becomes cavi-
tated. S. mutans is thought to be a stable colonizer in
the oral cavity, but when the oral cavity undergoes major
physiologic changes such as xerostomia, changes to the
oral microbial flora can often be found [20]. Lactobacil-
lus, in addition to S. mutans, is a recognized etiologic
agent of dental caries. Lactobacillus metabolizes sugars
into lactic acid that sits on teeth and is capable of dis-
solving enamel, also resulting in cavitation. Lactobacillus
is responsible for the high progression rate of existing
caries. C. albicans is observed in infections occurring
after radiation therapy and is the causative organism of
candidiasis, or oral thrush [15].
In addition to changes in salivary flow, it is expected
that the composition of whole saliva would be affected
by radiation therapy and that compositional changescould also be evaluated for improvements in gland func-
tion. In one study, it was found that salivary flow rate,
amylase activity, and protein content decreased follow-
ing radiation therapy in the oral cavity of cancer patients
[21]. Salivary amylase is one of the major protein com-
ponents of parotid saliva, and if angiogenesis leads to a
restoration of function in radiation-damaged acinar cells,
salivary amylase should be measurably increased in
whole saliva [21].
It has been shown that insulin growth factor-1 (IGF-1)
injections following radiation therapy can gradually re-
store salivary gland function. In one study, total amylase
content in irradiated glands was increased following
intra-parotid IGF-1 injections, which demonstrates that
an increase in function of the salivary acinar cells oc-
curred [22]. IGF-1 is a potent activator of the threonine
protein kinase Akt pathway in salivary acinar cells in vitro,
and in vivo [23]. In a mouse model, apoptosis of acinar cells
following irradiation was actually suppressed in those cells
expressing the active form of Akt that were pre-treated with
IGF-1 [23]. These results correspond with preservation of
salivary gland function, and salivary flow rate [23].
In another study it was demonstrated that endothelial
nitric oxide synthase (eNOS) is a modulator of angio-
genesis, and that Akt activates eNOS via a phosphoryl-
ation pathway [24]. Endothelial cells, specifically in
response to vascular endothelial growth factor-A
(VEGF-A) or IGF-1, induce this phosphorylation path-
way [23]. It was found that upon the addition of an inhibi-
tor of Akt signaling, VEGF-A and IGF-1 concentrations
were reduced, leading to reduced levels of phosphorylated
eNOS, which in turn lead to the conclusion that Akt plays
an important role in the regulation of angiogenesis [23]. It
has been hypothesized that in a hyperoxic environment,
VEGF-A activity is enhanced, which supports the use of
HBOT as a means to achieve angiogenesis in a damaged
tissue sample [25]. One study noted that acellular
macrophage-conditioned media alone was sufficient to in-
duce angiogenesis, and this was directly due to the pres-
ence of VEGF-A [26]. This is due to the fact that VEGF-A
is significantly involved in the recruitment of other pro-
angiogenic factors, including IGF-1 [26]. It is expected
that HBOT will result in a clinically significant rise in both
VEGF-A and IGF-1 salivary concentrations
Exploring the mechanisms of salivary gland injury may
provide some insight on specific factors and pathways
involved in salivary gland dysfunction. One theory
concerning the mechanism of salivary gland damage is
apoptosis of the salivary acinar cells. It has since been
suggested that inhibition of the p53 apoptosis pathway
might prove to be an effective method of protecting the
salivary glands during therapeutic radiation treatment
[27]. Radiation therapy has been shown to cause DNA
damage, which activates the p53 pathway leading to cell
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ally, an in vivo study revealed that following head and
neck irradiation, there was a marked increase in phos-
phorylated p53 and apoptosis in mouse parotid glands,
and a resultant decrease in their salivary flow [27]. One
review in the literature discussed that when cells are
subjected to a hypoxic environment, or otherwise defi-
cient in oxygen availability, they undergo adaptive re-
sponses to establish a new homeostasis in order to
survive under such conditions [28]. If hypoxia lasts too
long, or is too severe, the cells eventually undergo apop-
tosis [28]. This review discussed the possibility that the p53
pathway may be dependent on induction by and, competi-
tion with, hypoxia-inducible factor-1alpha (HIF-1 alpha)
under prolonged hypoxic conditions. HIF-1alpha ordinarily
helps to stabilize the transcription of target genes involved
with the growth of blood vessels such as VEGF-A [28]. In
cases of severe hypoxia, the drastic rise in HIF-1alpha levels
that is produced under such conditions actually induces the
stabilization of p53 [28]. Ordinarily, under hypoxic condi-
tions, p53 levels fall as part of a protective mechanism to
prevent apoptosis [28]. The resultant high levels of both
factors create co-activator competition: while p53 stabilizes,
HIF-1alpha activity decreases, leading to apoptosis [28].
Also, in cases of anoxia, a p53-dependent HIF-1alpha deg-
radation pathway that leads to high levels of apoptosis was
identified [28]. Sermeus mentioned that there are at least
three different mechanisms used by p53 to inhibit angio-
genesis. First, it increases the production of anti-angiogenic
factors, such as thrombospondin-1. Second, p53 directly in-
hibits the HIF-1alpha pathway. Third, p53 transcriptionally
represses genes encoding pro-angiogenic factors, including
VEGF-A and basic fibroblast growth factor [28]. Perhaps
one of the reasons why patients experience permanent
damage to their salivary glands and marked xerostomia is
due to the severe or prolonged hypoxic/anoxic environ-
ment caused by radiation therapy. Utilizing the advantages
of HBOT, there is the potential for HBO to target specific
points of insult and to modulate dysfunctional salivary
gland tissue.
Conclusion
Our study is anticipated to show the efficacy of HBOT
in reducing xerostomia for head and neck cancer pa-
tients who have undergone radiation. We also intend to
prove that HBOT will reduce costs associated with
treating irradiated tissue. Annual cost of dental care in-
curred by head and neck cancer patients in the US has
not been reviewed; however, as previously mentioned,
head and neck cancers have been ranked the 8th most
expensive cancers in the US today [1]. In addition to the
millions spent on patients’ medical care (i.e. radiother-
apy, chemotherapy, histographic sectioning, transfusions,
surgical reconstruction, etc.), dental care costs aresubstantial in the US for this group and contribute to
the detrimental effect to standard of living, especially
since prevalence of patient dental insurance is low com-
pared to medical insurance [1]. A UK study conducted in
2011 estimated that the dental costs of post-operative treat-
ment for resected squamous cell carcinoma ranges from ap-
proximately £5,790 - £23,212 (approximately $9,218.87-
$36,958.28), depending on the site of the primary lesion
[29]. This included the cost of oral surgery, oral and max-
illofacial surgery, palliative care, and pain management
[29]. A US study published in 2012 reported a total annual
health care spending for oral, oral pharyngeal and salivary
gland cancers in their first year after diagnosis to be
$79,151 for patients with commercial health insurance [2].
Patients receiving all three treatments (surgery, radiation,
and chemotherapy) had the highest costs of care, from
$96,520 in the Medicare population to $153,892 in the
Commercial population [2]. If HBOT proves to be an ef-
fective treatment modality for resolution of hyposalivation,
it may have the potential to significantly reduce medical
and dental costs incurred for patients following tumor re-
section and radiation therapy. Most importantly, HBOT
could possibly improve the quality of life for head and
neck cancer patients by reducing the negative affects of ra-
diation [30].
After reviewing the above principles of HBOT as well
as mechanisms of salivary gland tissue injury from radi-
ation, it would be clinically significant to perform this
research study in order to explore possible ways of pre-
serving and restoring salivary gland function. This pro-
spective study proposal targets the specific angiogenic and
anti-apoptotic factors that have the potential to demon-
strate favorable clinical results. There is the expectation
that evaluating the above theories may eventually provide
information to determine if HBOT can be used as a
prophylactic therapy for head and neck radiation therapy,
or be integrated into the protocol for recovery for head
and neck irradiated patients.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TH carried out the literature search and writing of the first and final draft of
the manuscript. CS also performed a literature search, writing of the final
draft and responding to peer reviewers. LW, JL, MWR, JA, MT, BN and TL
wrote the initial study proposal, which serves as the basis to this manuscript.
MT, BN and TL were staff and faculty advisors. All authors read and approved
the final manuscript.
Author details
1Department of Anesthesiology, Loma Linda University Medical Center,
11234 Anderson St., Loma Linda, CA 92354, USA. 2Department of Respiratory
Care, Loma Linda University Medical Center, 11234 Anderson St., Loma Linda,
CA 92354, USA. 3Loma Linda School of Dentistry, 11092 Anderson St., Loma
Linda, CA 92354, USA. 4Loma Linda University, 11060 Anderson St., Loma
Linda, CA 92350, USA. 5Department of Respiratory Care, Loma Linda
University Medical Center, 11234 Anderson St., Loma Linda, CA 92354, USA.
6Department of Restorative Dentistry, Loma Linda University School of
Hadley et al. Medical Gas Research 2013, 3:15 Page 5 of 5
http://www.medicalgasresearch.com/content/3/1/15Dentistry, 11092 Anderson St., Loma Linda, CA 92354, USA. 7Department of
Medicine, Division of Pulmonary and Critical Care Medicine, Loma Linda
University Medical Center, 11234 Anderson St., Loma Linda, CA 92354, USA.
Received: 13 April 2013 Accepted: 25 June 2013
Published: 2 July 2013References
1. Lee JM, Turini M, Botteman MF, Stephens JM, Pashos CL: Economic burden
of head and neck cancer. A literature review. Eur J Health Econ 2004,
5(1):70–80.
2. Jacobson J, et al: The cost burden of oral, oral pharyngeal and salivary
gland cancers in three groups: commercial insurance, medicare, and
Medicaid. Head Neck Onc 2012, 4:15.
3. Forner L, Hyldegaard O, von Brockdorff AS, et al: Does hyperbaric oxygen
treatment have the potential to increase salivary flow rate and reduce
xerostomia in previously irradiated head and neck cancer patients?
A pilot study. Oral Oncol 2011, 47(6):546–51.
4. National Institute of Dental and Craniofacial Research. https://www.nidcr.nih.
gov/OralHealth/Topics/.
5. Chambers MS, Garden AS, Kies MS, Martin JW: Radiation-induced
xerostomia in patients with head and neck cancer: Pathogenesis, impact
on quality of life, and management. Head Neck J Sci Special Head Neck
2004, 26(9):796–807.
6. Dirix P, Nuyts S, Poorten VV, Delaere P, Van den Bogaert W: The influence
of xerostomia after radiotherapy on quality of life. Support Care Cancer
2008, 16(2):171–79.
7. Guggenheimer J, Moore PA: Xerostomia - Etiology, recognition and
treatment. J Am Dent Assoc 2003, 134(1):61–69.
8. Kan T, Kodani K, Michimoto K, Fujii S, Ogawa T: Radiation-Induced Damage
to Microstructure of Parotid Gland: Evaluation Using High-Resolution
Magnetic Resonance Imaging. Int J Radiat Oncol Biol Phys 2010,
77(4):1030–38.
9. Dirix P, Nuyts S: Evidence-based organ-sparing radiotherapy in head and
neck cancer. Lancet Oncol 2010, 11:85–91.
10. Burlage FR, Coppes RP, Meertens H, Stokman MA, Vissink A: Parotid and
submandibular/sublingual salivary flow during high dose radiotherapy.
Radiother Oncol 2001, 61(3):271–74.
11. Thom SR, Bhopale VM, Velazquez OC, Goldstein LJ, Thom LH, Buerk DG:
Stem cell mobilization by hyperbaric oxygen. Am J Physiol Heart Circ
Physiol 2005, 290:1378–1386.
12. Marx RE, Ames JR: The Use of Hyperbaric Oxygen Therapy in Bony
Reconstruction of the Irradiated and Tissue-deficient Patient. J Oral
Maxillofac Surg 1982, 40(7):412–420.
13. Feldmeier J, Carl U, Hartmann K, Sminia P: Hyperbaric Oxygen: does it
promote growth or recurrence of malignancy? Undersea Hyperbaric Med
Society Inc 2003, 30:1–18.
14. Marx RE: Radiation Injury to Tissue. In Hyperbaric Medicine Practice. 3rd
edition. Edited by Kindwall EP, Whelan HT. Flagstaff, AZ: Best Publishing
Company; 2008.
15. Cankar K, Finderle Z, Jan J: The effect of hyperbaric oxygenation on
postradiation xerostomia and saliva in patients with head and neck
tumours. Caries Res 2011, 45(2):136–41.
16. Dawes C: How much saliva is enough for avoidance of xerostomia? Caries
Res 2004, 38(3):236–40.
17. Williamson RA: An experimental study of the use of hyperbaric oxygen to
reduce the side effects of radiation treatment for malignant disease.
Int Assoc Oral maxillofacial Surgeons 2007, 36:533–540.
18. Marx RE: Osteoradionecrosis: a new concept of its pathophysiology.
J Oral Maxillofac Surg 1983, 41:283–288.
19. Knighton DR: Mechanisms of Wound Healing. In Hyperbaric Medicine
Practice. Edited by Kindwall EP. Flagstaff, AZ: Best Publishing Company;
1995.
20. Meng L, Liu J, Peng B, Fan M, Nie M, Chen Z, Gan Y, Bian Z: The
persistence of Streptococcus mutans in nasopharyngeal carcinoma
patients after radiotherapy. Caries Res 2005, 39:484–9.
21. Chitra S, Shyamala Devi CS: Effects of radiation and alpha-tocopherol on
saliva flow rate, amylase activity, total protein and electrolyte levels in
oral cavity cancer. Indian J Dent Res 2008, 19(3):213–8.22. Grundmann O, Fillinger JL, Victory KR, Burd R, Limesand KH: Restoration of
radiation therapy-induced salivary gland dysfunction in mice by post
therapy IGF-1 administration. BMC Cancer 2010, 10:417.
23. Mitchell GC, Fillinger JL, Sittadjody S, et al: IGF1 activates cell cycle arrest
following irradiation by reducing binding of ΔNp63 to the p21
promoter. Cell Death Dis 2010, 1:e50.
24. Michell BJ, Griffiths JE, Mitchelhill KI, et al: The Akt kinase signals directly to
endothelial nitric oxide synthase. Curr Biol 1999, 9(15):845–8.
25. Hopf HW, Gibson JJ, et al: Hyperoxia and angiogenesis. Wound Healing
Society 2005, 13(6):558–564.
26. Jensen JA, Hunt TK, Scheuenstuhl H, Banda MJ: Effect of lactate, pyruvate,
and pH on secretion of angiogenesis and mitogenesis factors by
macrophages. Lab Invest 1986, 54:574–578.
27. Avila JL, Grundmann O, Burd R, Limesand KH: Radiation-induced salivary
gland dysfunction results from p53-dependent apoptosis. Int J Radiat
Oncol Biol Phys 2009, 73(2):523–9.
28. Sermeus A, Michiels C: Reciprocal influence of the p53 and the hypoxic
pathways. Cell Death Dis 2011, 2:e164.
29. Kim K, Amonkar MM, Hogberg D, Kasteng F: Economic burden of resected
squamous cell carcinoma of the head and neck in an incident cohort of
patients in the UK. Head Neck Oncol 2011, 3(1):47.
30. Teguh DN, Levendag PC, et al: Early hyperbaric osygen therapy for
reducing radiotherapy side effects: early results of a randomized trial in
oropharyngeal and nasopharyngeal cancer. Int J Radiation Oncol Biol Phys
2009, 75(3):711–716.
doi:10.1186/2045-9912-3-15
Cite this article as: Hadley et al.: Does hyperbaric oxygen therapy have
the potential to improve salivary gland function in irradiated head and
neck cancer patients?. Medical Gas Research 2013 3:15.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
